1. Home
  2. UAA vs IMNM Comparison

UAA vs IMNM Comparison

Compare UAA & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Under Armour Inc.

UAA

Under Armour Inc.

HOLD

Current Price

$5.07

Market Cap

2.3B

ML Signal

HOLD

Logo Immunome Inc.

IMNM

Immunome Inc.

HOLD

Current Price

$24.87

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UAA
IMNM
Founded
1996
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Apparel
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
2.5B
IPO Year
2005
2020

Fundamental Metrics

Financial Performance
Metric
UAA
IMNM
Price
$5.07
$24.87
Analyst Decision
Hold
Strong Buy
Analyst Count
16
10
Target Price
$6.48
$32.80
AVG Volume (30 Days)
6.8M
951.9K
Earning Date
05-12-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
51.40
EPS
N/A
N/A
Revenue
$4,966,370,000.00
$6,941,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$1.57
$1,127.34
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.13
$8.93
52 Week High
$8.15
$30.06

Technical Indicators

Market Signals
Indicator
UAA
IMNM
Relative Strength Index (RSI) 32.56 42.00
Support Level $4.83 $19.28
Resistance Level $6.13 $27.14
Average True Range (ATR) 0.17 1.08
MACD 0.02 -0.48
Stochastic Oscillator 14.29 1.54

Price Performance

Historical Comparison
UAA
IMNM

About UAA Under Armour Inc.

Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America, Asia-Pacific, Europe, and Latin America. Consumers of its performance-based clothing and shoes include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through wholesale partners, company-owned digital channels, and approximately 440 company-owned outlet and full-price stores. The Baltimore-based firm was founded in 1996 and is led by controlling shareholder Kevin Plank.

About IMNM Immunome Inc.

Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

Share on Social Networks: